ICL Acquires Lavie Bio’s Technology Platform from Evogene

ICL has completed the acquisition of Lavie Bio’s technology platform, including its bank of microbes and commercial offerings, from Evogene. This strategic move enhances ICL’s capabilities in agricultural biologicals, aligning with its ongoing expansion in the sector.

Original excerpt: ICL acquires Lavie Bio’s technology platform, its bank of microbes, and its current commercial offerings from Evogene…

Source: AgFunderNews